COMPANY

Bond Biosciences

HQ: Parkville, MO source · bond.bio ↗

Keywords: gastroenterology hemochromatosis Hereditary Hemochromatosis BBI-001

Location: Parkville, MO · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Raised $7.61M (Form D filed Apr 8, 2026; amended Oct 5, 2026). SEC Form D 0001014108-26-000021 (Apr 8, 2026)
Evidence (1 event)
- Apr 8, 2026 · SEC Form D 0001014108-26-000021
  Name of Issuer: Bond Biosciences, Inc.; CIK: 1824224; Address: Parkville, MO; Submission type: D; Filing date: 2026-04-08; Industry Group: Other Health Care; Date of First Sale: 2026-04-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 5342880; Federal exemptions: 06b || Name of Issuer: Bond Biosciences, Inc.; CIK: 1824224; Address: Parkville, MO; Submission type: D/A; Filing date: 2026-06-04; Industry Group: Other Health Care; Date of First Sale: 2026-04-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 5927939; Federal exemptions: 06b || Name of Issuer: Bond Biosciences, Inc.; CIK: 1824224; Address: Parkville, MO; Submission type: D/A; Filing date: 2026-10-05; Industry Group: Other Health Care; Date of First Sale: 2026-04-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 7614879; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

May 4, 2026 Trial start Phase 1/Phase 2: A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis source ↗
Mar 28, 2022 Trial start Phase 1: A Study to Evaluate BBI-001 in Hereditary Haemochromatosis (HH) Patients and Iron Deficient Volunteers source ↗

2027-02 (ESTIMATED) · Phase 1/Phase 2 · A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis · NCT07371793

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07371793	A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis	Phase 1/Phase 2	Recruiting	May 4, 2026	2027-02 (estimated)
NCT05238207	A Study to Evaluate BBI-001 in Hereditary Haemochromatosis (HH) Patients and Iron Deficient Volunteers	Phase 1	Terminated	Mar 28, 2022	May 4, 2023 (actual)